IR-Med, Inc. 8-K

What Happened
IR-Med, Inc. announced a private placement that closed May 31, 2026, issuing 250,000 shares of common stock and warrants to buy up to 250,000 additional shares; the Company reported aggregate gross proceeds of $19,054. Purchasers were the chairman and several directors who each bought shares at $0.10 per share and received matching warrants exercisable at $0.10 per share for five years. Separately, on May 28, 2026, the Board approved option grants to insiders: 5,040,000 options to Chairman Oded Bashan, 3,236,519 options to Director Aharon Klein, and 2,779,988 options to Director Yaniv Cohen. Each option grant vested immediately, has a ten-year term and an exercise price of $0.001 per share; the options were granted outside the Company’s 2020 Incentive Stock Option Plan.

Key Details

• Offering closed May 31, 2026: 250,000 common shares and 250,000 warrants; aggregate gross proceeds $19,054.
• Purchasers were company insiders: Oded Bashan, Yechiel Even, Ron Mayron, Aharon Klein, Yaniv Cohen, and Ohad Bashan (individual purchase amounts listed in the filing).
• Warrants: exercise price $0.10, five-year term.
• Stock options: total of 11,056,507 options granted (5,040,000; 3,236,519; 2,779,988), fully vested, ten-year term, $0.001 exercise price, granted outside the 2020 plan.

Why It Matters

• Financing and insider purchases: The private placement raised a small amount ($19k) and was subscribed by insiders, which shows insiders participated in the transaction but did not bring substantial new capital. The securities are unregistered and were sold under exemptions (Section 4(a)(2)/Rule 506(b) and Regulation S).
• Potential dilution: The large option grants and outstanding warrants, if exercised, could materially increase the number of shares outstanding and dilute existing shareholders. Options are deeply in-the-money relative to the nominal exercise price ($0.001) only if market value exceeds that level; warrants exercise at $0.10.
• Governance note: Options were issued outside the existing option plan and fully vested at grant—items investors often view as material to future equity compensation and dilution.